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SUMMARY
Anemia, iron deficiency anemia (IDA), and iron deficiency (ID) are highly
prevalent in renal transplant recipients (RTR). Anemia is associated with
poor outcome, but the role of ID is unknown. Therefore, we aimed to
investigate the association of ID, irrespective of anemia, with all-cause
mortality in RTR. Cox regression analyses were used to investigate
prospective associations. In 700 RTR, prevalences of anemia, IDA, and ID
were 34%, 13%, and 30%, respectively. During follow-up for 3.1 (2.7–3.9)
years, 81 (12%) RTR died. In univariable analysis, anemia [HR, 1.72 (95%
CI: 1.11–2.66), P = 0.02], IDA [2.44 (1.48–4.01), P < 0.001], and ID [2.04
(1.31–3.16), P = 0.001] were all associated with all-cause mortality. In
multivariable analysis, the association of anemia with mortality became
weaker after adjustment for ID [1.52 (0.97–2.39), P = 0.07] and disap-
peared after adjustment for proteinuria and eGFR [1.09 (0.67–1.78),
P = 0.73]. The association of IDA with mortality attenuated after adjust-
ment for potential confounders. In contrast, the association of ID with
mortality remained independent of potential confounders, including ane-
mia [1.77 (1.13–2.78), P = 0.01]. In conclusion, ID is highly prevalent
among RTR and is associated with an increased risk of mortality, indepen-
dent of anemia. As ID is a modifiable factor, correction of ID could be a
target to improve survival.
Transplant International 2016; 29: 1176–1183
Key words
anemia, iron deficiency, kidney transplantation, mortality
Received: 5 April 2016; Revision requested: 4 May 2016; Accepted: 25 July 2016; Published
online: 13 September 2016
Introduction
Post-transplant anemia is associated with an increased risk
of graft failure, cardiovascular mortality, and all-cause
mortality in renal transplant recipients (RTR) [1–3].
Iron deficiency (ID) is highly prevalent in RTR and is
one of the main contributors to post-transplant anemia
[4,5]. The decreased intestinal uptake of iron as a con-
sequence of increased hepcidin and IL-6 concentrations,
which exist as a result of the pro-inflammatory state
that renal transplantation constitutes [6,7], may con-
tribute to a frequent occurrence of functional ID. In
addition, increased consumption of iron as a conse-
quence of enhancement of erythropoiesis after successful
transplantation in response to recovery of renal function
may further augment the functional ID [8]. Inadequate
iron stores at the time of transplantation, blood loss
during the surgical procedure, and frequent post-trans-
plant venipunctures may also contribute to the occur-
rence of ID [8]. It has indeed been shown that 60% of
ª 2016 The Authors. Transplant International published by John Wiley & Sons Ltd on behalf of Steunstichting ESOT.
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RTR without ID at the time of transplantation devel-
oped ID in a period of 6 months after transplantation
[9].
Conventionally, ID is linked to anemia. However, in
addition to its role in hemoglobin and oxygen trans-
port, iron plays a pivotal role in enzyme activity of a
number of enzymes linked to energy metabolism and
in other oxygen-binding proteins such as myoglobin
[10]. To date, potential consequences of ID (with and
without anemia) in transplantation are unknown. The
aim of this study was to validate the impact of anemia,
and to assess the impact of iron deficiency anemia




All RTR (aged ≥18 years) that were at least 1 year post-
transplantation were approached for participation dur-
ing outpatient clinic visits between 2008 and 2011, as
described previously [11]. RTR were all transplanted at
the University Medical Center Groningen, Groningen,
the Netherlands, and had no history of drug or alcohol
abuse, as reported in the patient records. Written
informed consent was obtained from 707 (87%) from
the 817 initially invited RTR. For the analyses, we
excluded patients with missing data on iron status
parameters (n = 7), resulting in 700 RTR eligible for
analyses. The study protocol was approved by the insti-
tutional review board (METc 2008/186). The study pro-
tocol adhered to principles of the Declaration of
Helsinki and was consistent with the Principles of the
Declaration of Istanbul as outlined in the ‘Declaration
of Istanbul on Organ Trafficking and Transplant
Tourism’.
Iron status parameters
Blood was drawn in the morning. Transferrin was mea-
sured using an immunoturbidimetric assay (Cobas c
analyzer, Modular P system, Roche diagnostics, Man-
nheim, Germany). Serum ferritin concentrations were
determined using the electrochemiluminescence
immunoassay (Modular analytics E170, Roche diagnos-
tics, Mannheim, Germany). Serum iron was measured
using photometry (Modular P800 system; Roche diag-
nostics, Mannheim, Germany). Transferrin saturation
[TSAT (%)] was calculated as 100 9 serum iron
(lmol/l)/25 9 transferrin (g/l) [12]. ID was defined as
TSAT <20% and ferritin <300 lg/l. Anemia was defined
as Hb<13 g/dl (M) or <12 g/dl (F).
Statistical analysis
Data were analyzed using IBM SPSS software, version
22.0 (SPSS Inc., Chicago, IL, USA) and R version 3.0.1
(Vienna, Austria). Data were expressed as mean  SD
when normally distributed or as median with interquar-
tile range (IQR) in the case of skewed distribution. The
baseline characteristics of patients without anemia and
ID, and patients with anemia, IDA, or ID are shown in
Table 1.
Kaplan–Meier curves were used to demonstrate the
effect of the presence of ID and/or anemia, anemia,
IDA, and ID on survival. Differences in survival rates
were tested using the Cox–Mantel log-rank test.
Cox regression analyses were used to investigate
prospective associations of anemia, IDA, and ID with
all-cause mortality. Various models were built to adjust
for potential confounders. Model 1 was considered as
crude Cox regression analysis. Model 2 was adjusted for
age and sex; model 3 was additionally adjusted for ane-
mia in the case of ID or for ID in the case of anemia;
model 4 was additionally adjusted for eGFR and pro-
teinuria.
As secondary analyses for the association between
anemia, IDA, and ID with mortality, we adjusted for
several potential confounders in multivariable Cox
regression models (Table 3). After adjustment for age,
sex, eGFR, and proteinuria, we adjusted in separate
models for lifestyle factors and comorbidities (model 2;
diabetes mellitus, systolic blood pressure, BMI, alcohol
use, and smoking), for medication use (model 3; ACE
inhibitors, diuretics, and CNI inhibitors), for inflamma-
tion (model 4; hs-CRP), and for heart failure (model 5;
NT-proBNP).
As sensitivity analysis, we assessed the association of
hemoglobin as continuous variable with mortality in the
multivariable analysis rather than anemia as a dichoto-
mous variable and by using another definition of ID,
namely TSAT<20% and ferritin <200 lg/l [13]. Regard-
ing the specific iron status parameters, we assessed the
association between serum ferritin, TSAT, and serum
iron on all-cause mortality in univariable and multivari-
able Cox regression analyses. We used Cox regression
analyses with restricted cubic splines with three knots to
test for potential nonlinearity of the prospective associa-
tions of ln-transformed ferritin, TSAT, and serum iron
with all-cause mortality. All tests were two-sided, and a
P-value of <0.05 was considered statistically significant.
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Results
Baseline characteristics
We included 700 RTR (age 53  13 years; 57% males)
with a median (interquartile range) duration after trans-
plantation of 5.4 (1.9–12.0) years. Mean eGFR was
52.3  20.2 ml/min/1.73 m2. Mean hemoglobin con-
centration was 13.2  1.8 g/dl, serum iron
concentration was 15.3  6.0 lmol/l, ferritin concentra-
tion was 118 (55–222) lg/l, and TSAT was 25  11%.
Anemia, iron deficiency anemia (IDA), and ID occurred
in 237 RTR (34%), 90 RTR (13%), and 208 RTR
(30%), respectively (Fig. 1). Mean corpuscular volume
(MCV) was 90  7 fl in the anemic RTR, 87  7 fl in
those with IDA, and 88  6 fl in those with ID. RTR
with anemia were more often male, had the lowest
eGFR, and used more ACE inhibitors compared with
Table 1. Baseline characteristics.
Variables
Patients without anemia








Age (years) 53  12 53  14 55  13 54  12
Sex (male, %) 132 (38) 131 (55) 46 (51) 99 (48)
BMI (kg/m2) 27  5 26  5 27  5 28  5
Systolic blood pressure (mmHg) 135  16 138  19 140  18 137  17
Diastolic blood pressure (mmHg) 82  10 82  12 82  11 83  11
Never smoker (%) 41 38 36 36
Former smoker (%) 38 46 56 50
Current smoker (%) 13 11 7 9
Unknown smoking status (%) 8 4 2 5
No alcohol consumption (%) 9 10 12 9
Alcohol 0–10 (g/day) 52 59 64 68
Alcohol 10–30 (g/day) 22 19 18 15
Alcohol >30 (g/day) 6 3 0 2
Renal parameters
Time since transplantation (years) 6.4 (3.0–12.8) 4.7 (1.2–11.2) 3.7 (1.0–9.3) 4.3 (1.1–10.0)
eGFR (ml/min/1.73 m2) 58.5  19.2 42.1  17.8 44.6  18.6 50.4  19.6
Proteinuria (≥0.5 g/24 h) (%) 16 33 34 28
Comorbidities
Anemia (%) 0 100 100 43
Diabetes mellitus (%) 21 24 37 35
Treatment
ACE inhibitor (%) 31 39 30 26
AII antagonist (%) 13 18 20 18
Beta-blocker (%) 62 65 67 66
Diuretic (%) 35 48 56 49
Calcineurin inhibitor (%) 49 68 72 66
Proliferation inhibitor (%) 82 84 84 86
Statin use (%) 54 55 54 49
mTOR inhibitor (%) 2 2 4 2
EPO-stimulating agents (%) 2 4 4 2
Iron supplements (%) 4 9 6 5
Laboratory measurements
Hb (g/dl) 14.3  1.1 11.4  1.0 11.1  1.0 12.7  1.8
MCV (fl) 91  5 90  7 87  7 88  6
Iron (lmol/l) 18  5 13  6 8  3 9  3
Ferritin (lg/l) 156 (86–257) 97 (43–203) 37 (21–69) 46 (27–97)
TSAT (%) 31  9 23  12 12  5 14  4
NT-pro-BNP (pg/ml) 159 (72–393) 425 (197–1090) 550 (245–2299) 350 (127–1069)
hs-CRP (mg/l) 1.3 (0.6–3.5) 1.7 (0.8–4.9) 2.9 (0.8–6.5) 2.5 (1.0–6.3)
Azathioprine and mycophenolate mofetil were considered as proliferation inhibitors; cyclosporine and tacrolimus as calcineurin
inhibitors. Diabetes mellitus was defined as serum glucose >7 mmol/l or the use of antidiabetic drugs.
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those with IDA and ID. RTR with IDA were at shorter
duration after transplantation, had the highest systolic
blood pressure, had higher concentrations of C-reactive
protein and NT-proBNP levels, and had the highest
prevalence of diabetes mellitus as comorbidity as com-
pared to the other patients with anemia or with ID. In
contrast, RTR with ID were more often female and had
a higher eGFR compared with the RTR with anemia
and IDA (Table 1).
Anemia, IDA, ID, and mortality
During a median follow-up for 3.1 (2.7–3.9) years, 81
(12%) RTR died, of which 38 (47%) due to cardiovas-
cular causes. Other causes of death were infection
(24%), malignancy (16%), and miscellaneous and other
causes (14%). Kaplan–Meier survival curves for RTR
with or without ID and/or anemia, for RTR with and
without anemia, for RTR with and without IDA, and
for RTR with and without ID are shown in Fig. 2. It
appears that there is a marked difference in survival
between RTR having anemia, IDA, or ID compared
with those without (log-rank test P = 0.01 for anemia;
P < 0.001 for IDA, and P = 0.001 for ID).
In univariable Cox regression analysis, anemia [HR,
1.72 (95% CI: 1.11–2.66), P = 0.02], IDA [2.44 (1.48–
4.01), P < 0.001], and ID [2.04 (1.31–3.16), P = 0.001]
were associated with mortality (Table 2).
In multivariable Cox regression analysis models, the
association of anemia with mortality remained signifi-
cant after adjustment for age and sex [1.72 (1.11–2.66),
P = 0.02]. However, the association of anemia with
mortality lost statistical significance after adjustment for
ID [1.52 (0.97–2.39), P = 0.07]. Moreover when addi-
tional adjustment was performed for eGFR and
proteinuria, the association of anemia with mortality
disappeared altogether [1.09 (0.67–1.78), P = 0.73].
The association of IDA with mortality remained
after adjustment for age and sex [2.09 (1.27–3.45),
P = 0.004]. When additional adjustment was per-
formed for eGFR and proteinuria, the association of
IDA with mortality lost significance [1.67 (0.99–2.82),
P = 0.05].
The association of ID with mortality remained after
adjustment for age and sex [1.94 (1.25–3.01),
P = 0.003]. Further adjustment for anemia did not
materially affect the association of ID with mortality
[1.77 (1.13–2.78), P = 0.01]. When additional adjust-
ment was performed for eGFR and proteinuria, the
association of ID with mortality remained significant
[1.74 (1.10–2.73), P = 0.02; Table 2].
Secondary analyses of association with mortality
In secondary analyses, we aimed to investigate whether
the association of anemia, IDA, and ID with mortality
is independent of other potential confounders (comor-
bidities, medication use, inflammation, and heart fail-
ure; Table 3). In these analyses, in which we adjusted
for these other potential confounders, the associations
of anemia and ID with mortality remained materially
unchanged, that is, virtually absent for anemia and sig-
nificant for ID, while that of IDA remained independent
of adjustment for most of the potential confounders,
but lost significance after adjustment for NT-proBNP
(Table 3).
Definition of ID and individual ID definition
components
As sensitivity analysis, after adjustment for age, sex,
eGFR, and proteinuria, we adjusted the association of
ID with mortality for hemoglobin as continuous vari-
able rather than anemia as a dichotomous variable. The
association became weaker after adjustment for hemo-
globin as continuous variable [1.54 (0.97–2.45),
P = 0.07]. In another sensitivity analysis, we assessed
the association of ID with all-cause mortality using an
alternative definition of ID (TSAT<20% and ferritin
<200 lg/l). The association of this definition of ID with
mortality remained also materially unchanged after
adjustment for age, sex, eGFR, proteinuria, and anemia
[1.66 (1.05–2.63), P = 0.03].
Next to the definition of ID, we tested the individual
iron status parameters, that is, serum ferritin, TSAT,







Figure 1 Prevalences of anemia, IDA, and ID in the RTR cohort.
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ferritin as continuous variable was not associated with
risk of mortality [1.01 (0.81–1.26), P = 0.95]. This is
likely the consequence of a nonlinear relationship of fer-
ritin with mortality. In Fig. 3a, a cubic restricted spline
depicting the U-shaped association of ferritin with all-
cause mortality is shown. Indeed, we found significant
deviances from linear associations of ln ferritin with all-
cause mortality (P = 0.03), which lost statistical signifi-
cance after adjustment for the potential confounders
(P = 0.07). When divided into quintiles, the lowest
quintile [2.48 (1.08–5.79), P = 0.03] and the highest
quintile of ferritin concentrations [2.61 (1.16–5.87),
P = 0.02] were associated with higher risk of mortality
when compared with the fourth quintile, in a model in
which we adjusted for potential confounders (age, sex,
eGFR, proteinuria, and anemia). In further adjustment
for hs-CRP, the strength of the relationship in the low-
est quintile [2.22 (0.95–5.18), P = 0.07] and in the
highest quintile of ferritin [2.35 (1.04–5.29), P = 0.04]
decreased moderately.
In univariable analysis, TSAT as a continuous vari-
able was inversely associated with risk of mortality [0.97
(0.95–0.99), P = 0.007] (Fig. 3b). After adjustment for
potential confounders (age, sex, eGFR, proteinuria, and
anemia), a trend remains, but statistical significance is
lost [0.98 (0.96–1.00), P = 0.06].
Serum iron as a continuous variable was in univari-
able analysis inversely associated with risk of mortality
Figure 2 Kaplan–Meier curves for the difference in patient survival in (a) renal transplant recipients with or without ID and/or anemia (b) with
or without anemia; (c) with or without iron deficiency anemia (IDA); (d) with or without iron deficiency (ID).
Table 2. Cox proportional hazard analysis for anemia, IDA, and ID in predicting all-cause mortality.
Variable
Anemia IDA ID
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Univariable 1.72 (1.11–2.66) 0.02 2.44 (1.48–4.01) <0.001 2.04 (1.31–3.16) 0.001
Model 1 1.72 (1.11–2.66) 0.02 2.09 (1.27–3.45) 0.004 1.94 (1.25–3.01) 0.003
Model 2 1.52 (0.97–2.39) 0.07 – – 1.77 (1.13–2.78) 0.01
Model 3 1.09 (0.67–1.78) 0.73 1.67 (0.99–2.82) 0.05 1.74 (1.10–2.73) 0.02
Model 1: Adjustment for age and sex.
Model 2: Model 1 + adjustment for ID (outcome: anemia) or anemia (outcome: ID).
Model 3: Model 2 + adjustment for eGFR and proteinuria.
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[0.94; (0.90–0.98), P = 0.003] (Fig. 3c). After adjust-
ment for potential confounders (age, sex, eGFR, pro-
teinuria, and anemia), the association weakened [0.96
(0.92–1.00), P = 0.08].
Discussion
The main finding of this study was that ID, indepen-
dently of anemia, is prospectively associated with all-
cause mortality in stable RTR. We confirmed previous
reports that anemia is associated with an increased risk
of mortality in RTR [2,14]. However, in our study, the
association of anemia with all-cause mortality lost sta-
tistical significance after adjustment for ID. The associa-
tion was lost altogether after additional adjustment for
renal function, whereas the association of ID with mor-
tality was not influenced by either anemia or renal
function. The strong association of ID with all-cause
mortality together with the high prevalence of ID in
RTR identifies ID, even in the absence of anemia, as a
possible target for treatment in these patients.
Anemia is common in RTR [15]. In the present
study, in keeping with earlier reports, one-third of the
population was anemic [4,16] and anemia was associ-
ated with mortality [14]. However, when adjusted for
ID, the magnitude of the association of anemia with
mortality decreased and lost statistical significance, pos-
sibly implicating that ID is one of the main driving
forces of the association of anemia with mortality. Fur-
thermore, after further adjustment for kidney function
parameters, the association of anemia with mortality
disappeared. In contrast, ID remained strongly associ-
ated with mortality, independent of both anemia and
kidney function.
Table 3. Secondary analysis for the association of anemia, IDA, and ID with all-cause mortality.
Variable
Anemia IDA ID
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Model 1 1.19 (0.73–1.95) 0.48 1.67 (0.99–2.82) 0.05 1.76 (1.12–2.75) 0.01
Model 2 1.20 (0.74–1.96) 0.46 1.78 (1.04–3.05) 0.04 1.83 (1.16–2.89) 0.009
Model 3 1.29 (0.79–2.10) 0.31 1.86 (1.05–3.28) 0.03 1.75 (1.08–2.83) 0.02
Model 4 1.24 (0.76–2.01) 0.39 1.79 (1.03–3.11) 0.04 1.81 (1.13–2.90) 0.01
Model 5 1.22 (0.75–1.99) 0.42 1.74 (1.02–2.98) 0.04 1.76 (1.10–2.80) 0.02
Model 6 1.12 (0.68–1.85) 0.66 1.48 (0.83–2.65) 0.19 1.71 (1.06–2.76) 0.03
Model 1: Adjustment for age, sex, eGFR, and proteinuria.
Model 2: Model 1 + adjustment for time since transplantation.
Model 3: Model 2 + adjustment for diabetes mellitus, SBP, BMI, alcohol, and smoking.
Model 4: Model 2 + adjustment for medication use (ACE inhibitors, diuretics, CNI inhibitors, and iron supplements).
Model 5: Model 2 + adjustment for inflammation (hs-CRP).
Model 6: Model 2 + adjustment for NT-pro-BNP.
Figure 3 Associations between serum ferritin (a), TSAT (b), and serum iron (c) and risk of all-cause mortality. The line in the graph represents
the risk of all-cause mortality. The gray area represents the 95% CI of the HR.
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Traditionally, ID is clinically linked mainly to ane-
mia. However, in addition to hemoglobin, iron is a key
component of a number of cellular enzymes, for exam-
ple, oxidases, catalases, and cytochromes, and other pro-
teins such as myoglobin. As a result, iron is not only
essential for oxygen transport but also plays a pivotal
role in, for instance, the synthesis of DNA, electron
transport, and cellular proliferation and differentiation
[17,18].
Estimation of iron status is complex, and the cutoffs
for the clinical diagnosis of ID are arbitrarily defined
[19]. For ID, we used the definition commonly used
(e.g. in CKD), TSAT<20% and ferritin <300 lg/l [20].
This definition includes both functional and absolute
iron deficiency states and uses a combination of two fre-
quently used iron markers, TSAT and ferritin [20–22].
As a sensitivity analysis for the definition of ID, we
used another frequently used definition [13,] basically
rendering identical results. Also the individual iron sta-
tus components (serum ferritin, TSAT, and serum iron)
were associated with mortality, although the relation-
ship between ferritin and mortality was nonlinear.
When divided into quintiles, both high and low ferritin
concentrations were associated with mortality. These
findings are in concordance with studies in RTR and
other patient groups [23,24]. These results point out to
the possibility that both ID and iron overload may
have deleterious effects on patient survival. It should be
mentioned that serum ferritin concentrations are, in
addition to iron overload, also elevated in other condi-
tions such as inflammation, cardiovascular disease, and
malignancies [23,25]. However, after adjustment for hs-
CRP the association of high serum ferritin with mortal-
ity remained more or less unchanged. Indeed, iron
overload is considered potentially harmful in nondialy-
sis and dialysis patients receiving IV iron [26].
Recently, the pros and cons of intravenous iron therapy
were evaluated during the KDIGO ‘Controversies
Conference on Iron Management in Chronic Kidney
Disease’ [19].
We did not investigate the mechanism(s) through
which ID leads to increased mortality risk, and there-
fore, the causative mechanism can only be matter of
speculation. Clinically, ID is associated with reduced
cardiac performance and pulmonary hypertension.
Indeed, post-transplant anemia is associated with worse
outcomes such as more fatigue, reduced exercise capac-
ity, lower quality of life, and higher incidence of conges-
tive heart failure [27]. In agreement with this
speculation adjusting for NT-proBNP (Table 3) dimin-
ished the association between ID and mortality, possibly
indicating that cardiac performance was one of the
mediators between iron deficiency and all-cause
mortality.
The strengths of our study is the cohort that was uti-
lized for the analysis, a large cohort of well-character-
ized, stable RTR including extensive data on
anthropometric and dietary factors, lifestyle, and medi-
cation use that allowed for adjustments for many
confounders and without loss to follow-up.
One of the main limitations of our study is that a
readily available clinical gold standard of functional
and absolute ID does not exist. In some studies, in
addition to markers of iron load (ferritin) and iron
transport availability (TSAT), functional markers of
iron incorporation in the red cell such as hypochro-
mic red blood cells or reticulocyte hemoglobin content
are used. However, these markers are difficult to use
in clinical studies and are not routinely measured and
superiority is not established over commonly used
clinical definition. Another limitation is that we used
a single baseline measurement of hemoglobin levels
and iron status. However, most epidemiological stud-
ies use a single baseline measurement for studying the
association of variables with outcomes, which as a
consequence adversely affects the strength of the asso-
ciation of these variables with outcomes. In other
studies, it was shown that when intra-individual vari-
ability of these variables was taken into account, a
strengthening of the association with outcome, that is,
coronary heart disease occurred as compared to the
association of a single measurement [28,29]. As a con-
sequence, it is likely that when including multiple
measurements, the association of iron deficiency with
mortality would be even more pronounced. Finally, as
with any observational study, there may be unmea-
sured or residual confounding despite the substantial
number of potentially confounding factors for which
we adjusted.
In conclusion, we are the first to show that ID,
independently of anemia, is associated with a higher
risk of all-cause mortality in RTR. Further research is
needed to reveal the mechanisms through which ID
leads to higher risk of all-cause mortality. Moreover,
further investigation is needed to assess whether ana-
logue to heart failure patients, achievement of an ade-
quate iron status, irrespective of hemoglobin levels, can
be a possible new therapeutic target in RTR. As ID is
a relatively easily modifiable factor, randomized con-
trolled trials should focus on correction of ID in RTR
in an effort to improve patient survival after
transplantation.
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